Dual‐fluorescence staining showed that, compared with the liver fibrosis group (treated with CCL4+PBS), the expression of ALB (a hepatocyte‐specific marker) in hepatocytes in the fibrotic area of the treatment group (treated with CCL4+EXOs) was increased, whereas the expression of KRT19 (a marker for bile ducts) was diminished (Figure 6b,c). This evidence concerns the gene CCL4 and Hepatic fibrosis.